High persistence and efficacy of ustekinumab as a first-line biological therapy in inflammatory bowel disease: a real-world cohort study

Živa Šubic; David Drobne; Gregor Novak

doi:10.1080/00365521.2025.2597263

December 8, 2025Scandinavian Journal of Gastroenterology

High persistence and efficacy of ustekinumab as a first-line biological therapy in inflammatory bowel disease: a real-world cohort study

View Full Paper

Ask AI

Bookmark

Share

Key Points

Ustekinumab treatment achieves high persistence in inflammatory bowel disease patients, enhancing long-term management.
The study reports substantial rates of clinical, biochemical, and endoscopic remission associated with ustekinumab.
Real-world cohort study shows ustekinumab's role as an effective first-line biological therapy for inflammatory bowel disease.
These findings highlight the potential for ustekinumab to improve outcomes in individuals with inflammatory bowel disease.

Implication

Observational analysis shows high treatment-persistence and remission rates in inflammatory bowel disease patients receiving ustekinumab, suggesting effectiveness in real-world settings.

Abstract

First-line treatment with ustekinumab demonstrates high treatment-persistence and is associated with substantial rates of clinical, biochemical, and endoscopic remission in patients with IBD.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Šubic et al. (2025) studied this question.

synapsesocial.com/papers/694020e82d562116f28fad9b https://doi.org/10.1080/00365521.2025.2597263

View Full Paper

Ask AI

Bookmark

Share

High persistence and efficacy of ustekinumab as a first-line biological therapy in inflammatory bowel disease: a real-world cohort study

Key Points

Implication

Abstract

Discussion

Cite This Study

High persistence and efficacy of ustekinumab as a first-line biological therapy in inflammatory bowel disease: a real-world cohort study

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading